Inari Medical, Inc. is a commercial-stage medical device company committed toward developing products to treat and change the lives of patients suffering from venous diseases. Its initial product offering comprises 2 minimally-invasive, novel catheter-based mechanical thrombectomy devices. It built its products purposely on the basis of the specific characteristics of the venous system and the treatment of the two distinct indications of venous thromboembolism or VTE (deep vein thrombosis and pulmonary embolism/ PE). Its FlowTriever product is the first thrombectomy system, which is FDA-cleared, used for the treatment of PE. Its advanced systems & processes to control the key relationships between its sales representatives and treating physicians like cardiologists, radiologists, helps it to quickly iterate products, launch and execute physician education and training programs and scale its sales organization. The company markets and sells its products to hospitals across the U.S.
| Revenue (Most Recent Fiscal Year) | $493.63M |
| Net Income (Most Recent Fiscal Year) | $-1.64M |
| PE Ratio (Current Year Earnings Estimate) | 631.41 |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 8.15 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 10.77 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 906.95 |
| Pre-Tax Margin (Trailing 12 Months) | -9.29% |
| Net Margin (Trailing 12 Months) | -13.68% |
| Return on Equity (Trailing 12 Months) | -10.09% |
| Return on Assets (Trailing 12 Months) | -6.60% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.77 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.40 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 1.58 |
| Book Value per Share (Most Recent Fiscal Quarter) | $8.07 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.13 |
| Earnings per Share (Most Recent Fiscal Year) | $0.13 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.35 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Common Shares Outstanding | 58.54M |
| Free Float | 52.34M |
| Market Capitalization | $4.68B |
| Average Volume (Last 20 Days) | 1.06M |
| Beta (Past 60 Months) | 1.02 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 10.60% |
| Percentage Held By Institutions (Latest 13F Reports) | 90.98% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |